Clin Osteol 2005; 10(1): 7-11

Strontium renelate - a prospective compound for the treatment of osteoporosisArticles

S. Kutilek

In vitro studies gave evidence that strontium ranelate stimulates bone formation and has an inhibitory effect on bone resorption. Preclinical studies on animal models of osteoporosis further confirmed that application of strontium leads to an increase in bone mass and has a preventive effect on bone loss. Placebo-controlled phase II studies proved that 1 to 2 years treatment with strontium ranelate in daily doses of 1 000-2 000 mg resulted in significant increase in bone mineral density. Phase III studies gave evidence that treatment with daily doses of 2 000 mg strontium ranelate signifi­ cantly reduced both vertebral and nonvertebral fracture risk. Strontium ranelate is therefore a very perspective agent in the treatment of osteoporosis.

Keywords: strontium, bone, fractures, osteoporosis. Osteologický bulletin 2005(10(1):7-11

Published: June 11, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kutilek S. Strontium renelate - a prospective compound for the treatment of osteoporosis. Osteologický bulletin. 2005;10(1):7-11.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Meunier PJ. Large clinical trials for osteoporosis. Therapie 2003;58:415-420. Go to original source...
    2. Meunier PJ. Bone-forming agents. In: Papapoulos SE, ed. Osteoporosis. Amster­ dam, Elsevier Science 1996:305-313.
    3. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: The critical need for a uni­ form nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20:177-184. Go to original source...
    4. Reginster JV, Deroisy R, Jupsin I. Strontium ranelate: a new paradigm in the treat­ ment of osteoporosis. Drugs of Today 2003;39:89-101. Go to original source...
    5. Pors Nielsen S. The biological role of strontium. Bone 2004;35:583-588. Go to original source...
    6. Marie PJ, Ammann P, Boivin G, et al. Mechanisms of action and therapeutic po­ tential of strontium in bone. Calcif Tissue Int. 2001;69:121-129. Go to original source...
    7. Marie PJ. Optimizing bone metabolism in osteoporosis: insight into the pharma­ cologic profile of strontium ranelate. Osteoporosis Int 2003; 14 (Suppl. 3):S9-S12 Go to original source...
    8. Marie PJ. Strontium ranelate: A novel mode of action optimizing bone formation and resorption. Osteoporos Int 2004;Dec 2: Epub ahead of print Go to original source...
    9. Canalis E, Hott M, Deloffre P, et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996;18:517-523. Go to original source...
    10. Barbara A, Delannoy P, Denis BG, Marie PJ. Normal matrix mineralization indu­ ced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism 2004; 53:532-537. Go to original source...
    11. Ammann P. Strontium ranelate: mode of action and benefits for bone quality. Osteoporos Int. 2003;14:105 (SY21). Go to original source...
    12. Ammann P. Strontium ranelate: A novel mode of action leading to renewed bone quality. Osteoporos Int 2004;Dec 2: Epub ahead of print Go to original source...
    13. Le Gerros RZ, Lin S, LeGeros JP, et al. Strontium ranelate preserves bone crystal characteristics and bone mineral reactivity. Osteoporos Int. 2004;15:116 (P420).
    14. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bo­ ne marrow macrophage differentiation. Eur J Pharmacol 2002;450:11-17. Go to original source...
    15. Takahashi N, Sasaki T, Tsouderos Y, Suda T. S12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003;18:1082-1087 Go to original source...
    16. Mentaverri R, Hurtel AS, Kamel S Robin B, Brazier M. Strontium directly stimu­ lates osteoclast apoptosis. Osteoporos Int. 2004;15:92 (P345).
    17. Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 2001;16:299-308. Go to original source...
    18. Quinn SJ, Kifor O, Chattopadhyay N, et al. Strontium is a full agonist of the ex­ tracellular calcium-sensing receptor (CaR) transfected in human embryonic kid­ ney cells. Osteoporos Int 2004;15:107 (P392).
    19. Coulombe J, Faure H, Robin B, et al. Stimulatory effects of strontium ranelate (S12911) on the rat and mouse cation-sensing receptor. J Bone Miner Res 2001;16 (Suppl 1):SU500
    20. Brown EM. Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporos Int 2003;14 (Suppl 3):25-34. Go to original source...
    21. Coulombe J, Faure H, Robin B, Ruat M. In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem Biophys Res Commun 2004;323:1184-90. Go to original source...
    22. Pi M, Quarles LD. A novel cation-sensing mechanism in osteoblasts is a molecu­ lar target for strontium. J Bone Miner Res 2004;19:862-869. Go to original source...
    23. Dahl SG, Allain P, Marie PJ, et al. Incorporation and distribution of strontium in bone. Bone 2001;28:446-53 Go to original source...
    24. Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate inc­ reases vertebral bone mass without deleterious effect in mice. Metabolism 2002; 51:906-911. Go to original source...
    25. Amman P, Robin B, Bonjour JP, et al. Long-term exposure to strontium ranelate dose-dependently increases bone strength in intact female rats. Bone 2001; 28 (Suppl 1):220:P537S.
    26. Amman P, Robin B, Rizzoli R. Long-term exposure to strontium ranelate dose-dependently increases intrinsic bone duality. J Bone Miner Res 2003;18(Suppl 2):SU398
    27. Amman P, Shen V, Robin B, et al. Long-term exposure to strontium ranelate do­ se-dependently increases bone strength in intact male and female rats. Osteoporos Int 2002;13 (Suppl 1):P66SU
    28. Marie P, Amman P, Shen V, et al. Evidence that strontium ranelate increases bo­ ne quality in rats by improving bone strength and architecture. Bone 2003;32 (Suppl. 5):OR29 W7
    29. Amman P, Rizzoli R. Strontium ranelate dose-dependently increases bone strength and intrinsic bone quality in intact female rats. Osteoporos Int. 2004;15: 93(P345).
    30. Shen V, Robin B, Bazot D, Tupinon-Mathieu I. Histomorphometric evaluation of the proximal tibia methaphysis after a long-term oral administration of S12911 in female rats. J Bone Miner Res 2002;17(Suppl. 1):SU369.
    31. Shen V, Liu C, Marque V, et al. Histomorphometric evaluation of the tibio-fibular junction after a long-term oral administration of S12911 in female rats. J Bone Miner Res 2002;17(Suppl. 1):SU368.
    32. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;8:607-615. Go to original source...
    33. Bain S, Shen V, Zheng H, et al. Long-term treatment with strontium ranelate in­ creases histomorphometric indices of bone formation in ovariectomized rats. J Bo­ ne Miner Res 2003;18(Suppl. 2):SU403.
    34. Bain S, Shen V, Zheng H, Dupin-Roger I. Strontium ranelate treatment prevents ovariectomy-induced bone loss in rats by maintaining the bone formation at a high level. Osteoporos Int. 2004;15:116 (P419).
    35. Bain S, Shen V, Hara P, Leininger R, Dupin-Roger I. Treatment of ovariectomi­ zed rats with strontium ranelate improves bone strength and bone quality. Osteoporos Int. 2004;15:102 (P376).
    36. Hott M, Deloffre P, Tsouderos Y, Marie PJ. S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 2003;33:115-123. Go to original source...
    37. Oste L, Bervoets AR, Behets GJ, et al. Time-evolution and reversibility of stronti­ um-induced osteomalacia in chronic renal failure rats. Kidney International 2005;67:920-930. Go to original source...
    38. Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S12911) administration. J Bone Miner Res 1996;11(9):1302-1311. Go to original source...
    39. Boivin G, Farlay D, Panczer G, et al. Long-term strontium ranelate administration in monkeys: effects on mineral crystals and on the degree of mineralisation of bo­ ne. J Bone Miner Res 2001;16(Suppl 1):SA401.
    40. Boivin G, Meunier PJ. The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporos Int 2003;14(Suppl 3):19-24. Go to original source...
    41. Reginster JY. Strontium ranelate in osteoporosis. Curr Pharm Des 2002;8: 1907-1916. Go to original source...
    42. Reginster JY, Deroisy R, Dougados M, et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, doublemasked, dose­ ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002;13:925-931. Go to original source...
    43. Meunier PJ, Slosman DO, Delams PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis- A 2-year randomi­ zed placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-66. Go to original source...
    44. Reginster JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int 2003;14(Suppl. 3):56-65. Go to original source...
    45. Meunier PJ, Reginster JY. Design and methodology ofthe phase 3 trials for the cli­ nical development of strontium ranelate in the treatment of women with postme­ nopausal osteoporosis. Osteoporos Int 2003;14(Suppl. 3):66-76. Go to original source...
    46. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459 468. Go to original source...
    47. Christiansen C, Tanko LB. Uncoupling bone turnover with strontium ranelate: a promising agent for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2004;15:98 (P363).
    48. Reginster JY, Sawicki A, Devogelaer JP, et al. Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis. Osteoporosis Int 2002;13 (Suppl. 3):O14.
    49. Rizzoli R, Reginster JY, Diaz-Curiel M, et al. Patients at high risk of hip fracture benefit from the treatment with Strontium ranelate. Osteoporos Int. 2004;15:18 (OC39).
    50. Adami S, Meunier PJ, Devogelaar JP, et al. Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in caucasian women with postmenopausal osteoporosis. Osteoporos Int 2004;15:92 (P349).
    51. Compston J. Prevention of vertebral fractures by strontium ranelate in postmeno­ pausal osteoporosis. Osteoporos Int 2004;Oct 12:Epub ahead of print. Go to original source...
    52. Reginster JY, Rizzoli R, Balogh A, et al. Strontium ranelate reduces the risk of ver­ tebral fractures in osteoporotic postmenopausal women without prevalent verteb­ ral fracture. Osteoporos Int 2004;15:113 (P409).
    53. Delmas PD. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis. Osteoporos Int 2004;Dec 2: Epub ahead of print. Go to original source...
    54. Reginster JV, Lecart MP, Deroisy R, Lousberg C. Strontium ranelate: a new para­ digm in the treatment of osteoporosis. Expert Opin Investig Drugs 2004; 13: 857-64. Go to original source...
    55. Marquis P, Cialdella P, De la Loge C. Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Qual Life Res 2001;10:555-66. inzerát Biomin Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.